Cambridge University biotech spin-out Definigen has secured £1.3m ($2.13m) in series A funding in a round led by the university’s tech transfer unit Cambridge Enterprise, and joined by early-stage investor 24Haymarket and Cambridge-based biotech Abcam’s co-founder Jonathan Milner. Cambridge Enterprise’s involvement marks the largest investment made by the university through its seed funds in a…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
